Completed PHASE4 INTERVENTIONAL 2-arm NCT00361543

Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia (SERM)

Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia?

Sponsor: National Health and Medical Research Council, Australia

Conditions Schizoaffective Disorder Schizophrenia Schizophreniform Disorder

Interventions Lactose Capsules Raloxifene hydrochloride

Updated 5 times since 2017 Last updated: Jan 28, 2015 Started: Aug 31, 2006 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Schizoaffective Disorder and Schizophrenia, this trial is completed. The trial is conducted by National Health and Medical Research Council, Australia and has accumulated 5 data snapshots since 2006. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Aug 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Health and Medical Research Council, Australia
Stanley Medical Research Institute
The Alfred

Data source: The Alfred

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Melbourne, Australia